The Food and Drug Administration recently approved Edenbridge Pharmaceuticals' ethacrynic acid tablets.
The tablets are a potent diuretic intended for the treatment of edema.
The new treatment represents the first approved generic form of brand-name Edecrin tablets, which are produced by Canada-based Valeant Pharmaceuticals.
Edenbridge Pharmaceuticals, headquartered in Parsippany, N.J., plans to launch the ethacrynic acid tablets as soon as possible.
More articles on the drug market:
Sanofi, U.S. Army partner to speed up Zika vaccine development
Drugmakers hesitant to let generic rival Teva join PhRMA
Viewpoint: How drug coupons keep prices high